Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / By country / Japan

Peptide legality · Japan · updated 2026-09-22

Are peptides legal in Japan?

Restricted

Peptides are legal in Japan only as government-approved prescription medicines dispensed through licensed physicians and pharmacies; unapproved 'research' peptides such as BPC-157 and TB-500 have no Japanese approval and cannot lawfully be sold, advertised, or supplied for human use under the Pharmaceuticals and Medical Devices Act.

Legal status overview

Peptides in Japan are restricted: they are lawful only when they are approved prescription drugs obtained through the regulated medical system, while unapproved peptides cannot be sold or advertised for human use. Japan has no peptide-specific 'schedule'; instead all peptides intended for human use fall under the Pharmaceuticals and Medical Devices Act (薬機法/PMD Act), which requires Ministry of Health, Labour and Welfare (MHLW) approval and licensing before any product can be manufactured, imported for business, sold, or advertised. Approved GLP-1 peptides like semaglutide are prescription-only, while peptides with no Japanese approval remain outside the legal supply chain.

Key points

  • Japan has no peptide-specific statute or separate peptide schedule; peptides intended for human use are instead governed by the Pharmaceuticals and Medical Devices Act (薬機法/PMD Act), which requires MHLW approval and licensing before any product may be manufactured, imported for business, sold, or advertised. [2]
  • The PMD Act's regulatory targets, defined in Article 1, are pharmaceuticals, quasi-drugs, cosmetics, medical devices, and regenerative-medicine products, and peptides marketed for effects on the body fall within its definition of 'pharmaceuticals'. [3]
  • Article 68 of the PMD Act prohibits advertising the name, manufacturing method, indications, efficacy, or performance of unapproved drugs, which makes domestic marketing of peptides that hold no Japanese approval unlawful. [2]
  • MHLW has publicly warned that GLP-1 receptor agonists such as Mounjaro® and Rybelsus® are approved only for conditions like type 2 diabetes, that their safety and efficacy for beauty, slimming, or dieting have not been confirmed, and that person-to-person sale of these drugs over the internet is illegal. [2]
  • Travelers may bring a personal-use supply of prescription medicines into Japan without an import certificate only up to a one-month supply; larger quantities require a Yunyu Kakunin-sho (formerly Yakkan Shoumei) import certificate obtained from a Regional Bureau of Health and Welfare before arrival. [5]
  • For injectable peptides, Japan's rules require a Yunyu Kakunin-sho/Yakkan Shoumei for any personal import of injections or injectors exceeding a one-month supply, and only pre-filled syringes or self-injection kits may be carried in without prior permission. [6]
  • In November 2023 Japan approved semaglutide (Wegovy®) for chronic weight management, and the government simultaneously issued a guideline restricting which physicians may prescribe it, partly in response to concerns over out-of-pocket, diet-purposed use purchased online. [1]

Compound-by-compound status

BPC-157BPC-157 is an unapproved synthetic research peptide in Japan with no MHLW/PMDA marketing authorization, so it cannot lawfully be sold or advertised for human use and is distributed only outside the regulated drug-approval system. [7]
Semaglutide (GLP-1, e.g. Ozempic®/Wegovy®/Rybelsus®)Semaglutide is legal in Japan as a prescription-only medicine, with Wegovy® approved for chronic weight management (November 2023) and diabetes formulations approved for type 2 diabetes, but MHLW treats non-prescription cosmetic/slimming supply and person-to-person internet sales as unlawful. [1]
TB-500 (thymosin beta-4)TB-500 has no Japanese approval and falls under the PMD Act as an unapproved drug, meaning it cannot lawfully be sold or advertised for human use in Japan. [2]
Human growth hormone / somatropin (HGH-related peptides)Growth-hormone-related peptides are regulated under Japan's PMD Act, so somatropin is available only as an MHLW-approved prescription medicine while unapproved HGH-type 'research' peptides cannot be legally supplied for human use. [2]

Frequently asked questions

Can I buy peptides in Japan without a prescription?

No, in Japan approved peptide medicines such as GLP-1 drugs are prescription-only and must be obtained through a licensed physician and pharmacy, and MHLW considers person-to-person or online sale of these drugs illegal. [2]

Can I bring peptides into Japan for personal use when I travel?

You may bring up to a one-month personal-use supply of a prescription medicine into Japan without an import certificate, but any larger amount, and any injectable supply exceeding one month, requires a Yunyu Kakunin-sho (formerly Yakkan Shoumei) obtained from a Regional Bureau of Health and Welfare before you arrive. [5]

Is BPC-157 legal in Japan?

BPC-157 is not approved in Japan and is treated as an unapproved drug under the PMD Act, so it cannot legally be sold, advertised, or supplied for human use there. [7]

Is semaglutide (Ozempic®/Wegovy®) legal for weight loss in Japan?

Semaglutide is legal in Japan only as a prescription medicine; Wegovy® was approved for chronic weight management in November 2023 under a government guideline limiting who can prescribe it, and MHLW warns that using or selling GLP-1 drugs for beauty or slimming outside those rules is not sanctioned. [1]

Can a doctor in Japan prescribe peptides through telehealth or for weight loss?

Approved peptide medicines can be prescribed by licensed Japanese physicians, but for semaglutide the government restricted the number of physicians allowed to prescribe it and flagged concern over out-of-pocket, diet-purposed prescriptions obtained online. [1]

Sources

  1. Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions, Diabetes, Obesity and Metabolism (Wiley) (retrieved 2026-09-22)
  2. Japan Peptide Laws & Regulations, PeptideLaws.com (retrieved 2026-09-22)
  3. What is the Japanese Pharmaceutical and Medical Device Act?, Monolith Law Office (retrieved 2026-09-22)
  4. Bringing Medications into Japan, Embassy of Japan in the United States (retrieved 2026-09-22)
  5. Importing Medication to Japan, Yakkan Shoumei Instructions (Consulate-General of Japan in Chicago) (retrieved 2026-09-22)
  6. Q&A for those who are bringing medicines into Japan (Consulate-General of Japan in Seattle) (retrieved 2026-09-22)
  7. BPC-157 Peptide: Benefits, Safety, Legal Status, and Research, BSCG (retrieved 2026-09-22)

Last researched: 2026-09-22.

General information based on the sourced research above, not legal advice. Laws change and enforcement varies; for a specific situation in Japan, consult a licensed attorney or the national regulator.